Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update

Key Takeaways Krystal Biotech gained FDA approval to expand Vyjuvek's label to DEB patients from birth.The update allows at-home administration and flexibility in managing wound dressings.Approvals in Europe and Japan, plus U.S. growth, are expected to boost Vyjuvek sales.Krystal Biotech (KRYS) announced that the FDA has approved a label update of its marketed product, Vyjuvek (beremagene geperpavec-svdt), to include dystrophic epidermolysis bullosa ("DEB") patients from birth.Shares of Krystal Biotech were ...